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Background: Previous data from the literature reported blunted perception of airway
obstruction in severe asthmatics with near fatal asthma. Approximately 25% of patients
with asthma are current smokers.
Aim: To determine whether there is an alteration in perception of airway obstruction
during a non specific provocative challenge with methacholine in mild controlled
asthmatics who smoke.
Methods: Enrolled in this study were 50 subjects, including 26 mild asthmatics and 24
healthy subjects, all of them current smokers. The first objective was the sensitivity of
airway obstruction calculated by the regression slope linking the change in the visual
analogic scale (VAS) assessed by the patient and the fall in FEV1 during a methacholine
challenge.
Results: Asthmatics who smoke had a blunted perception of airway obstruction during the
bronchial challenge significantly different from that seen in healthy smokers (p ¼ 0.03).
This impaired dyspnea perception was inversely related to baseline VAS (r ¼ 0.29,
po0.05) and positively related to baseline FEV1 (r ¼ 0.35, po0.05). Perception of airway
obstruction was not correlated with age, sex, atopy or with airway inflammation features
such as exhaled NO or sputum eosinophils.
Conclusion: Mild asthmatics who smoke display reduced dyspnea perception during a non-
specific provocative challenge with methacholine. This altered perception of airway
obstruction does not relate to airway inflammation.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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l.com (S. Kleis).Introduction
The diagnosis and management of asthma is based on
a combination of clinical symptoms and lung function
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Perception of dyspnea in mild smoking asthmatics 1427measurement. However, altered perception of dyspnea, an
important symptom of asthma, may well obscure the
diagnosis1 and lead to inappropriate asthma management
thereby placing the patient at risk of severe exacerbations.
Evaluation of dyspnea is difficult because it is a subjective
perception. Sensitivity of asthmatics towards symptoms like
dyspnea is variable and patients can be classified in three
different categories: the ‘‘poor perceivers’’, the ‘‘moderate
perceivers’’ and the ‘‘high perceivers’’.2,3 Dyspnea percep-
tion has been previously studied in asthma4 and was
reported to be associated to some degree with the presence
of bronchial eosinophilic inflammation.5,6 The links between
near fatal asthma exacerbations and a blunted perception of
symptoms were investigated and controversial findings have
emerged.2,7 In most studies, dyspnea perception was found
to be higher in healthy subjects than in asthmatics but
impaired dyspnea perception in asthma seems to be
essentially limited to severe asthma.4
In developed countries, approximately 25% of asthmatic
patients are current smokers.8 Compelling evidence sug-
gests that smoking makes asthma worse. In the USA, the rate
of smokers among asthmatics is greater in adult asthmatics
visiting emergency rooms for asthma attacks.9 Inhalation of
cigarette smoke at rates as low as CO2 2 ppm induces a
significant fall of the FEV1 in subjects with bronchial hyper
reactivity.10 Sippel et al.11 reported a worse quality of life
and a poorer control of the disease in asthmatics who
smoked. It was reported that severe asthmatics who smoke
are at a higher risk of death from recurrent acute attacks
than those who quit.7 To date dyspnea perception in
asthmatics who smoke has not been investigated well.
We hypothesized that altered dyspnea perception
is a potential explanation of under treatment and poor
control in asthmatics who smoke. We aimed in the present
study to investigate dyspnea in mild smoking asthmatics
during methacholine bronchial challenge. Furthermore, we
sought any relationship between dyspnea perception and
airway inflammation as assessed by sputum eosinophils and
exhaled NO.Subjects and Methods
Subjects
The asthmatic subjects included in this study were recruited
among the patients attending our asthma clinic between
October 2004 and April 2005, while healthy subjects were
recruited among the hospital staff. Demographic and
functional characteristics of both healthy subjects and
asthmatics are given in Table 1. Both asthmatics and healthy
subjects were current smokers as reflected by elevated
urinary cotinine levels (Table 1). At the first contact, all
patients were counselled and encouraged to try to give up
smoking. Those who declined or failed were enrolled in the
study. The asthmatics belonged to the category of inter-
mittent or mild persistent controlled asthma according to
the last GINA guidelines.12 Asthma was diagnosed on the
basis of a clinical history of recurrent symptoms of
wheezing, coughing and breathlessness and the demonstra-
tion of a methacholine bronchial hyper reactivity with a
PC20Mo16mg/ml. None of the asthmatics had experiencedsevere asthma exacerbation in the past. The asthma was
well controlled as revealed by a short asthma control
questionnaire o1.5.13,14 The healthy subjects all had a
negative challenge with methacholine. Atopy was diagnosed
on the basis of positive skin prick tests towards common
aeroallergens of our area (mites, cat, dog, molds, grass and
birch pollens). This study and its design were approved by
the local ethic committee and all patients gave written,
informed consent.Methods
Study design
The study began with the skin prick tests followed by
measurement of exhaled NO. Then the challenge with
methacholine was carried out associated to evaluation of
the perception of dyspnea on a visual analogic scale (VAS).
The induced sputum was carried out the same day or a few
days later.Exhaled NO
We used a Nioxs machine, recommended by the ATS, with a
flow of 50ml/s. The average of three successive measure-
ments was retained and expressed in part per billion (pbb).Bronchial methacholine challenge
Before starting with the bronchial methacholine challenge,
a measure of the forced expiratory volume in 1 s (FEV1) and
vital capacity (VC) was carried out. Then the subject was
asked to inhale for 1min from several aerosols containing a
solution of methacholine of fourfold increasing concentra-
tions (from 0.06 to 16mg/ml). The nebuliser used was an
ultrasonic type (Devilbiss 2000, Sommerset, USA). One
minute after each aerosol, the subject was asked to produce
a forced expiration in a spirometer. This measure was
repeated twice and the best value of FEV1 was saved.
The fall of the FEV1 was compared to the baseline value. The
test was interrupted and considered as positive when the
FEV1 value fell by 20% or more compared to the baseline
value. The program then calculated by interpolation the
concentration of methacholine responsible for a reduction
of 20% of the FEV1. This concentration represented the
PC20M.Dyspnea perception
The two most current tools validated for dyspnea evaluation
are the Borg scale and the VAS.15,16 In this study, we used the
100mm VAS with the words minimum and maximum on
the left and right ends, respectively. After explanation of
the VAS, the patient was invited to indicate the intensity
of the dyspnea felt by a point (or a vertical line) on the VAS.
Dyspnea intensity was assessed before the test as 30 s after
each inhaled methacholine concentration. At the end of
the test, a linear regression was then applied between the
variations of the VAS compared to the starting value and the
fall of the FEV1 expressed as a percentage of the initial
value. A straight regression line was obtained. The slope
represents the sensitivity to dyspnea of the patient. A strong
sensitivity corresponds to a high value.
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Table 1 Demographic characteristics, functional and inflammatory characteristics of patients.
Group variable Asthmatics smokers N ¼ 26 Non-asthmatics smokers N ¼ 24
Sex ratio (M/F) 14/12 11/13
Age 38.5 (25–45) 24.5 (22–40.5)
Smoking history (pack-year) 7.9 (4–25) 5.1 (3–14)
Urinary cotinin (mg/l) 971 (776–1680) 1478 (671–1522)
Atopy 9 7
Inhaled steroids 7 0
Exhaled NO (ppb) 18.4 (9.8–28.5) 14.4 (10.7–24.8)
Baeline FEV1 (% pred) 96.4 (89.3–106.5) 106.8 (100.9–116.1)
Maximal fall in FEV1 (% of baseline) 26.95 (21.4–32.4) 7.7 (4–11.8)
PC20M (mg/ml) 3.49 (0.05–11) 416
Sputum eosinophils (%) 1.0 (0.0–5.0) 0.0 (0.0–0.0)
The values are expressed in medians and IQ 25–75 for continuous variables without normal distribution. Median values for NO and FEV1,
values of the geometric mean for the PC20M and values of the median for the sputum eosinophils. IQ 25–75.
S. Kleis et al.1428Sputum induction and processing
In order to obtain induced expectoration, the subject was
invited to inhale a 5% hypertonic saline solution with
ultrasonic nebulization for 3 5min (Devilbiss, 2000, Som-
merset, USA). An attempt at expectoration was carried out
after each 5min series after the subject had rinsed his
mouth. The administration of 400 mg salbutamol before the
test and during the saline inhalation (saline solution coupled
to salbutamol) made it possible to avoid excessive bronch-
oconstriction.17 FEV1 was measured every 5min. A fall of
more than 20% of the FEV1 led to stopping the test. The
sputa were treated by dilution in PBS for homogenisation
and the cells treated the second time by a mucolytic agent
(dithiothreitol or DTT.0.01M) before performing of cytos-
pins. Cell differential was calculated after counting 400 non-
squamous cells.Statistical analysis
The results were expressed as mean (SEM) or median (IQR)
following the distribution of the variables. For the contin-
uous variables, a Mann–Whitney test was carried out to
compare the two groups. For the nominal variables, we used
the chi square test or the Fischer test. The correlations were
sought by the coefficients of Pearson or Spearman according
to the normal distribution or not of the variables. The
threshold of significance was fixed at po0.05. The statis-
tical program used was Statistica 6.0.&Results
There was no significant difference between groups with
regard to age, sex, tobacco, urinary cotinin, atopy, and
eNO (p40.05 for each variable) (Table 1). By contrast
smoking asthmatics had a raised sputum eosinophil
count as compared with healthy smokers (po0.05). No
difference was noticed regarding the other sputum cell
types. Baseline FEV1, whilst in the clinically normal range
in all subjects, was statistically lower in the asthmatic
groups than in the healthy subjects (po0.05). None had a
ratio FEV1/FVC o 70%.Maximal fall in FEV1 at the end of the methacholine
challenge was on average 27% (21.4–32.4%) in asthmatics vs.
8% (4–11.8%) in healthy subjects (Table 1).
Perception of dyspnea
There was no significant difference between the groups with
regard to baseline dyspnea assessed by baseline VAS.
Smoking asthmatics displayed a lower perception of metha-
choline-induced airway obstruction than healthy smokers
as reflected by a lower slope value DVAS/DFEV1 (p ¼ 0.03)
(Fig. 1). Neither the age, the sex nor atopy influenced the
perception of dyspnea (p40.05). Bronchial hyper respon-
siveness, as defined by PC20M, failed to correlate with the
slope. Likewise, there was no correlation between dyspnea
perception and exhaled NO and sputum eosinophils
(p40.05). However, we found a weak, but significant
correlation between the slope and baseline FEV1 value
(r ¼ 0.35, po0.05), and an inverse significant correlation
between the slope and the baseline value on the VAS
(r ¼ 0.29, po0.05).
Discussion
Blunted perception of dyspnea in asthmatics has often been
described in severe asthmatics.5 Our study shows that
current smoking may alter the perception of airway
obstruction induced by methacholine in a population of
mild asthmatics. We did not include in this study non-
smoking asthmatics; however, we found significant results
with altered dyspnea perception in smoking mild asthmatics
compared with smoking non-asthmatics. Our data indicate
that, in this population, the blunted perception appears to
be independent of the extent of eosinophilic airway
inflammation and bronchial hyperresponsiveness itself. This
is an original finding that may cast light on some clinical
observations.
The fact that smoking asthmatics poorly perceive acute
airway obstruction is likely to lead to underreport of
symptoms and thereby to a lack of recognition of asthma
among smokers. Thus it is conceivable that, in daily practice,
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Figure 1 Dyspnea perception expressed as the slope of the
regression line linking the change in VAS in mm from baseline to
the change in FEV1 in % fall from baseline.
Perception of dyspnea in mild smoking asthmatics 1429real asthma may be misdiagnosed as a tobacco related
chronic airway disease. Obviously, the misdiagnosis could
lead to poor management, placing the patient at risk of
severe asthma exacerbation, which might even occur in very
mild asthma.18 Another risk is represented by the potential
occurrence of a silent permanent airflow obstruction in those
patients left without anti-inflammatory treatment for a
variable period of time.19
Altered corticosteroid sensitivity has been extensively
reported in smoking asthmatics.20 Most of the scheduled or
unscheduled visits for asthma are symptoms, and more
specifically, dyspnea driven. Thus, the blunted dyspnea
perception found in the present study will prevent smoking
asthmatics from seeking an early and appropriate anti-
inflammatory treatment. Furthermore, it can contribute to
their lack of adherence to this therapy, which is a major
concern in mild asthma.
Our results could also provide an explanation as to why
the proportion of smokers remains surprisingly high in
asthma as compared to that seen in the general population.
The tolerance to the harmful effect of tobacco among
mild asthmatic smokers could be partially explained by
the reduced perception of bronchial obstruction. However,
long duration smoking habits in asthmatics make them
evolve later towards a non-reversible bronchial obstruction
with an accelerated decline of respiratory function.21
Indeed, asthma and tobacco are independent and additive
factors contributing to the decline of the respiratory
function.22
Smoking may contribute to the development and mani-
festations of severe asthma; asthmatic smokers are more
symptomatic, have more severe and frequent exacerbations
and emergency care needs; have a reduced response to
corticosteroids; and a more rapid decline in pulmonary
function. However, a recent wide study did not find a
relationship of smoking to severity or an accelerated decline
in FEV1.
23 Therefore, strategies to encourage smokingcessation are an important aspect of mild and severe
asthma management.
Massasso et al.24 showed that the COPD smokers did not
perceive the obstruction induced by methacholine as well as
asthmatic non-smokers. They postulated that poor dyspnea
perception in COPD smokers could be related to the effect
of tobacco smoke on the bronchial sensory nerves neuro-
transmitters. Indeed, a chronic depletion of these neuro-
transmitters such as substance P would induce a dysfunction
of these related sensory nerves.25 Later Chanez et al.26 did
not find the same results in asthmatics and COPD patients.
The results of Massasso could consequently reflect the effect
of the COPD itself rather than that of smoking. The team of
Ottanelli et al.27 showed, moreover, that among moderate
COPD smokers the perception of dyspnea during a test with
methacholine was variable and independent of the smoking
history of the patient.
In our study, the baseline FEV1 was slightly correlated
with the perception of dyspnea. So patients with a lower
FEV1 value, but nevertheless considered as clinically normal,
had a blunted perception of dyspnea. Our results are in
keeping with those reported by Bijl-Hoffland et al.4
However, contrary to the previous authors, we did not find
that severe bronchial hyper responsiveness was a risk factor
for limited dyspnea perception. This suggests that smoking
alters the relationship between bronchial hyper responsive-
ness and perception of airway obstruction. We also found an
inverse relationship between the dyspnea perception
induced by methacholine inhalation and baseline dyspnea.
The more breathless the patient felt before starting the
methacholine challenge, the less the methacholine induced
airway obstruction was perceived.
In our study, the perception of dyspnea was not correlated
to the eosinophils level in the induced sputum as opposed to
what In’t Veen et al.5 found. But our study population in
asthma included mild patients, whereas In’t Veen studied
severe asthmatics. Although slightly increased as compared
with healthy subjects, the eosinophil count in our smoking
asthmatics was rather low. Therefore, the range was
narrower than in a group of severe asthmatics making a
significant correlation unlikely. Similarly, no correlation was
found between exhaled NO, a marker of airway inflamma-
tion, and dyspnea perception. But it is well established that
exhaled NO is of little value in smoking asthmatics.28 In line
with this, our data show that smoking asthmatics had rather
similar exhaled NO levels to healthy smokers.
We recognize that our study has some limitations in that
we have assessed the bronchial hyper responsiveness
towards a direct constricting agent, i.e. methacholine. It
would also be of interest to investigate the relationship
between dyspnea and airway obstruction caused by indirect
agents such as adenosine or hypertonic saline.29 Another
limitation is the absence of comparison with non-smoking
asthmatics, however, this study has shown some significant
results without relation to inflammatory parameters.
Blunted dyspnea perception during methacholine challenge
in non-smoking mild asthma is already known.30
We conclude that mild asthmatics who smoke have an
impaired perception of bronchial obstruction caused by
methacholine inhalation compared to smoking non-asth-
matics. This finding may explain, in part, the tolerance
asthmatics may show to smoking.
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